ReCET technology, manufactured by Endogenex, uses a specialized catheter that ablates the duodenal mucosa with electroporation, enhancing sensitivity to endogenous insulin. In the first-in-human ...

AS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, has presented new data on its lead program PST-611, a DNA plasmid ...

PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, has presented new data on its lead ...

November 6, 2024MaxCyte, Inc. beats earnings expectations. Reported EPS is $-0.11, expectations were $-0.13. Operator: Hello ...

A live and archived webcast of the event will be available on the “Events” section of the MaxCyte investor relations website at https://investors.maxcyte.com/.

In this Thought Leader article., Ian Johnston from Cytiva discusses challenges related to process development, scaling technology, regulatory approvals, and GMP guidelines.

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ ...

New Technique Could Help Treat Aggressive Brain Tumors July 17, 2024 — Burst sine wave electroporation was ... a major cause of disability in human infants and ...

Human Brain Cancers Fire Electrical Impulses ... 2024 — Burst sine wave electroporation was found to cause less damage to cells and tissue but more disruption to the blood-brain ...

This innovative approach, which combines a novel procedure known as ReCET (Re-Cellularization via Electroporation Therapy ...

For patients with type 2 diabetes (T2D), duodenal recellularization via electroporation therapy (ReCET) is feasible and safe and can prevent the need for insulin therapy when combined with semaglutide ...